ECRI and ISMP Warn About Unverified Safety of Wellness Peptides in Patient Use

Patient Safety Concerns Regarding Wellness Peptides

In a recent warning, the ECRI (Emergency Care Research Institute) and the Institute for Safe Medication Practices (ISMP) have alerted consumers to the potential dangers posed by compounded peptides that are widely marketed in the wellness industry. These products, which are often promoted for muscle building, anti-aging, injury recovery, and immune support, are often not backed by sufficient clinical evidence or approval from regulatory bodies.

The Problem with Compounded Peptides

Many compounded peptides, such as BPC-157, TB-500, Melanotan II, and epitalon, exist in a legal gray area, lacking formal approval for human use by the FDA. As of April 2026, a federal policy change reclassified 12 of these peptides without accompanying new clinical evidence regarding their safety or efficacy. This change has been misleadingly interpreted by some as an endorsement of safety, which the ECRI and ISMP caution against.

Patients utilizing these wellness peptides have little reliable information about the products they are consuming. A significant number of studies regarding BPC-157, one of the most heavily marketed peptides, were performed on animals, with only one of thirty-six studies providing meaningful insight into its effects on humans. Alarmingly, the absence of Phase 1 safety data on humans and controlled trials raises serious questions about their safety.

Compounded peptide products are often sold through gray market channels labeled strictly for